The American Diabetes Association (ADA)“Standards of Care in Diabetes” includes the
ADA's current clinical practice recommendations and is intended to provide the components …

The American Diabetes Association (ADA)“Standards of Medical Care in Diabetes” includes
the ADA's current clinical practice recommendations and is intended to provide the …

Diabetic nephropathy has been traditionally diagnosed based on persistently high
albuminuria and a subsequent decline in glomerular filtration rate (GFR), which is widely …

Diabetic nephropathy (DN) is a major healthcare challenge. It occurs in up to 50% of those
living with diabetes, is a major cause of end‐stage kidney disease (ESKD) that requires …

This is an opportune time to publish the first KDIGO 2020 Clinical Practice Guideline for
Diabetes Management in Chronic Kidney Disease (CKD). Worldwide, the estimated number …

Diabetic kidney disease develops in approximately 40% of patients who are diabetic and is
the leading cause of CKD worldwide. Although ESRD may be the most recognizable …

The development and progression of diabetic kidney disease (DKD), a highly prevalent
complication of diabetes mellitus, are influenced by both genetic and environmental factors …

The American Diabetes Association (ADA)“Standards of Medical Care in Diabetes” includes
the ADA's current clinical practice recommendations and is intended to provide the …

The global nephrology community recognises the need for a cohesive plan to address the
problem of chronic kidney disease (CKD). In July, 2016, the International Society of …

Sodium-glucose cotransporter-2 (SGLT2) inhibitors, including empagliflozin, dapagliflozin,
and canagliflozin, are now widely approved antihyperglycemic therapies. Because of their …